论文部分内容阅读
肝血宝由浙江省中医药研究所负责研制,杭州前进制药厂生产。经浙江省中医药研究所、北京医科大学附属人民医院、哈尔滨医科大学附属二院和三院、浙江医科大学附属一院及杭州肿瘤医院等18个医疗单位临床验证,治疗各种不同原因引起的白细胞减少症总有效率达88.6％,对肿瘤病人化疗、放疗所致的白细胞减少症总有效率达96.8％,为目前治疗白细胞减少症首选药物。
Liver Blood Po is responsible for the development of Zhejiang Institute of Traditional Chinese Medicine, Hangzhou forward pharmaceutical production. The Zhejiang Provincial Institute of Traditional Chinese Medicine, Affiliated People’s Hospital Affiliated to Beijing Medical University, Second Affiliated Hospital of Harbin Medical University and Hospitals, First Affiliated Hospital of Zhejiang Medical University and Hangzhou Cancer Hospital and other 18 medical units, clinical validation and treatment of various causes The total effective rate of leukopenia was 88.6%. The total effective rate of leukopenia caused by chemotherapy and radiotherapy for cancer patients was 96.8%, which is the first choice of drug for the treatment of leukopenia.